Displaying One Session

Channel 1 Industry Satellite Symposia
Date
Wed, 05.05.2021
Time
19:00 - 20:00
Room
Channel 1
CCO - CDK4/6 inhibitors in early-stage HR+/HER2- breast cancer: Individualizing therapeutic decisions to improve patient outcomes Industry Satellite Symposia

Medical need to improve on standard therapies for HR+/HER2- EBC (ID 334)

CCO - CDK4/6 inhibitors in early-stage HR+/HER2- breast cancer: Individualizing therapeutic decisions to improve patient outcomes Industry Satellite Symposia

Individualizing therapeutic decision-making for patients with HR+/HER2- EBC (ID 337)

CCO - CDK4/6 inhibitors in early-stage HR+/HER2- breast cancer: Individualizing therapeutic decisions to improve patient outcomes Industry Satellite Symposia

Adjuvant therapy for patients with HR+/HER2- EBC at high risk of recurrence (ID 338)

CCO - CDK4/6 inhibitors in early-stage HR+/HER2- breast cancer: Individualizing therapeutic decisions to improve patient outcomes Industry Satellite Symposia

Debating optimal neoadjuvant therapy (ID 336)

CCO - CDK4/6 inhibitors in early-stage HR+/HER2- breast cancer: Individualizing therapeutic decisions to improve patient outcomes Industry Satellite Symposia

Future considerations on the horizon for HR+/HER2- EBC (ID 368)

CCO - CDK4/6 inhibitors in early-stage HR+/HER2- breast cancer: Individualizing therapeutic decisions to improve patient outcomes Industry Satellite Symposia

Summary, final thoughts and live Q&A (ID 339)

Lecture Time
19:45 - 19:55
Room
Channel 1
Date
Wed, 05.05.2021
Time
19:00 - 20:00